AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Ubrelvy (ubrogepant) by Year
Ubrelvy (ubrogepant) — International net revenues ($M) ($M)
AbbVie Ubrelvy (ubrogepant): $32M in FY2025, up 28.0% from a year earlier.
Latest, FY2025
32
Period ended Dec 31, 2025
Change on a year earlier
+28.0%
25 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ubrelvy (ubrogepant) — International net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 32 | +28.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 25 | +108.3% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 12 | – | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2024-02-20) ↗ |
Breakdown
What makes up ubrelvy (ubrogepant)
Cite this data
StockData. (2026). AbbVie Ubrelvy (ubrogepant) ($M), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ubrelvy-intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.